Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
Micro-ultrasound-Guided Focal Laser Ablation (MicroUSgFLA) Treatment for Management of Intermediate-Risk Prostate Cancer: Evaluation of Safety and Effectiveness
- Prostate Cancer (Adenocarcinoma)
- Low and Intermediate Risk Prostate Cancer
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- University Health Network, Toronto
- Enrolment target
- 7
- Started
- 30 April 2025
- Main results due
- 31 May 2028
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Ages 40 years to 85 years.
- Men only.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Men 40-80 years of age. * Histologically-proven intermediate-risk PCa (Gleason score 7, primary grade ≤ 4). * PCa clinical stage T1c or T2. * MRI/MicroUS site suspicious for cancer or cancer mapped to one prostate lobe. * Maximum dimension of MRI/MicroUS visible tumour ≤15mm. * Suspicious site on Prostate MRI/MicroUS must coincide with sector positive for cancer on biopsy. * Prostate specific antigen (PSA) level \< 15 ng/mL. * IPSS, ICIQ-UI-SF, IIEF-15 questionnaires completed prior to the procedure. * Life expectancy of greater than 10 years, based on co-morbidity not related to PCa. Exclusion Criteria: * Maximum dimension of MRI/MicroUS visible tumour \> 15 mm. * Patients medically unfit for focal therapy of the prostate. * Patients who are unwilling or unable to give informed consent. * Patients who have received androgen suppression therapy. * Patients who have received or are receiving chemotherapy for prostate carcinoma. * Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive) including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment. * Patients who have undergone radiation therapy for PCa or to the pelvis. * Any condition or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies). * Patients with a history of non-compliance with medical therapy and/or medical recommendations. * Patients who are unwilling or unable to complete the patient self-assessment questionnaires. * Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition. * Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days. * Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent)
What this study is about
In the sponsor’s own words, from the registry.
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.
Study sites(1)
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07339943. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me